Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

GlobeNewswire March 29, 2019

ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

GlobeNewswire March 13, 2019

ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

GlobeNewswire March 5, 2019

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

GlobeNewswire February 27, 2019

ObsEva SA to Participate in Upcoming Investor Conferences

GlobeNewswire February 22, 2019

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

GlobeNewswire January 23, 2019

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

GlobeNewswire December 20, 2018

ObsEva SA to Host R&D Investor Day December 7, 2018

GlobeNewswire November 28, 2018

ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes

GlobeNewswire November 27, 2018

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire November 7, 2018

ObsEva SA to Participate in November Investor Conferences

GlobeNewswire November 6, 2018

ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018

GlobeNewswire October 30, 2018

Report: Developing Opportunities within Just Energy Group, Tetra Technologies, Domtar, MacroGenics, ObsEva SA, and Magic Software Enterprises — Future Expectations, Projections Moving into 2018

GlobeNewswire October 19, 2018

ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting

GlobeNewswire October 9, 2018

ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018

GlobeNewswire October 4, 2018

ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)

GlobeNewswire October 2, 2018

Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain

GlobeNewswire September 27, 2018

ObsEva SA to Participate in September Investor Conferences

GlobeNewswire August 27, 2018

New Research: Key Drivers of Growth for ObsEva SA, Gran Tierra Energy, Constellium N.V, Just Energy Group, Hovnanian Enterprises, and First Majestic Silver — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire August 21, 2018

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018

GlobeNewswire August 10, 2018